Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Spark Therap (ONCE)

Spark Therap (ONCE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 4,032,178
  • Shares Outstanding, K 38,486
  • Annual Sales, $ 64,730 K
  • Annual Income, $ -78,820 K
  • 60-Month Beta 2.07
  • Price/Sales 62.82
  • Price/Cash Flow N/A
  • Price/Book 10.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -1.12
  • Number of Estimates 5
  • High Estimate -0.57
  • Low Estimate -1.49
  • Prior Year -1.26
  • Growth Rate Est. (year over year) +11.11%

Price Performance

See More
Period Period Low Period High Performance
1-Month
96.55 +8.51%
on 08/14/19
105.96 -1.12%
on 09/12/19
+5.85 (+5.91%)
since 08/13/19
3-Month
95.32 +9.91%
on 07/24/19
105.96 -1.12%
on 09/12/19
+5.24 (+5.26%)
since 06/13/19
52-Week
34.53 +203.42%
on 12/26/18
114.20 -8.26%
on 03/12/19
+45.73 (+77.46%)
since 09/13/18

Most Recent Stories

More News
Imvax Appoints John P. Furey as Chief Executive Officer

Imvax, Inc., a discovery and clinical-stage biotechnology company focused on the development of novel patient-specific vaccines and immunotherapy strategies, today announced that John P. Furey has been...

ONCE : 104.77 (-0.83%)
Platelet BioGenesis Raises $26 Million in Series A-1 Financing

Platelet BioGenesis, Inc. (PBG), the leader in stem cell-derived, on-demand human platelets (PLTs+(TM)) and platelet-based therapeutics, announced today that it has raised more than $26 million in Series...

ONCE : 104.77 (-0.83%)
ETFs Poised to Benefit from Gene Editing Revolution

Rising investments and growing technological advancement are favoring the genomic editing space. We take a look at a few ETFs that can cash in on this trend.

PBE : 49.80 (unch)
ARKG : 31.83 (-0.06%)
ONCE : 104.77 (-0.83%)
GNOM : 13.53 (-0.82%)
AGN : 166.14 (-0.13%)
EDIT : 25.50 (-2.26%)
IDNA : 25.92 (-0.49%)
Global Regenerative Medicine Market Driven by Cell Therapy, Tissue Engineered, Gene Therapy by Region and Forecast 2019-2024

ReportsnReports added Global Regenerative Medicine Market: Analysis By Type (Cell Therapy, Tissue Engineered, Gene Therapy) , By Application, By Region, By Country (2019 Edition) : Opportunities and Forecast...

ONCE : 104.77 (-0.83%)
NVS : 86.99 (-2.79%)
AMGN : 195.47 (+0.76%)
CELGZ : 0.57 (+11.33%)
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 3 September 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced...

ONCE : 104.77 (-0.83%)
Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the location of its 2019 Annual Meeting...

ONCE : 104.77 (-0.83%)
Sensorion Announces Appointment of John Furey, Former COO of Spark Therapeutics, as Independent Board Member

Regulatory News:

ONCE : 104.77 (-0.83%)
Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 31 July 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) ("Spark") today announced that Roche has extended the offering period of its previously announced tender...

ONCE : 104.77 (-0.83%)
Analysts Estimate Spark Therapeutics (ONCE) to Report a Decline in Earnings: What to Look Out for

Spark Therapeutics (ONCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ONCE : 104.77 (-0.83%)
Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised

Roche's (RHHBY) performance in the first half of 2019 is driven by solid strength in new drugs, which more than offset competition from biosimilars.

ONCE : 104.77 (-0.83%)
ABBV : 70.51 (-0.45%)
RHHBY : 34.4900 (+1.71%)
AMGN : 195.47 (+0.76%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Trade ONCE with:

Business Summary

Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in...

See More

Key Turning Points

2nd Resistance Point 106.56
1st Resistance Point 105.67
Last Price 104.77
1st Support Level 103.96
2nd Support Level 103.14

See More

52-Week High 114.20
Last Price 104.77
Fibonacci 61.8% 83.77
Fibonacci 50% 74.36
Fibonacci 38.2% 64.96
52-Week Low 34.53

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar